Format

Send to

Choose Destination
Front Cell Dev Biol. 2016 Sep 21;4:103. eCollection 2016.

Evaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal Cancer.

Author information

1
UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College DublinDublin, Ireland; Translational Oncology, Trinity Translational Medicine Institute, Department of Surgery, Trinity College Dublin, St. James's HospitalDublin, Ireland.
2
UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin Dublin, Ireland.
3
Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital Baltimore, MD, USA.
4
Trinity Translational Medicine Institute, Department of Surgery, Trinity College Dublin, St. James's Hospital Dublin, Ireland.

Abstract

Colorectal cancer is the third most common cancer worldwide and is associated with significant morbidity and mortality. Current pharmacotherapy options include cytotoxic chemotherapy, anti-VEGF, and anti-EGFR targeting drugs, but these are limited by toxic side effects, limited responses and ultimately resistance. Cysteinyl leukotriene (CysLT) signaling regulates intestinal homeostasis with mounting evidence suggesting that CysLT signaling also plays a role in the pathogenesis of colorectal cancer. Therefore, CysLT signaling represents a novel target for this malignancy. This review evaluates reported links between CysLT signaling and established hallmarks of cancer in addition to its pharmacological potential as a new therapeutic target.

KEYWORDS:

colorectal cancer; cysteinyl leukotriene; cysteinyl leukotriene receptor antagonist; eicosanoid; hallmarks of cancer; tumorigenesis

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center